Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Clinical Trial of AMG510 (Sotorasib) in Stage III Unresectable NSCLC KRAS p.G12C Patients and Medically Ineligible for Concurrent Chemo-radiotherapy

NCT05398094 is registered in ClinicalTrials.gov with Fundación GECP as lead sponsor.

NCT NCT05398094
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05398094 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Clinical Trial of AMG510 (Sotorasib) in Stage III Unresectable NSCLC KRAS p.G12C Patients and Medically Ineligible for Concurrent Chemo-radiotherapy
Lead sponsor
Fundación GECP
Phase
Phase 2
Overall status
Recruiting
Start date
March 21, 2022
Completion date
December 31, 2028
Enrollment
19 (estimated)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

kras p.g12c, non-small cell lung cancer stage iii